Molecular Medicine : MolMed at the 22nd ASGCT congress on continuous innovation in the production of viral vectors for clinical use.

PRESS RELEASE

MolMed at the 22nd American Society of Gene and Cell Therapy (ASGCT) congress on continuous innovation in the production of viral vectors for clinical use.

Milano (Italia), May 2nd 2019 - MolMed S.p.A. (MLMD.MI) (the "Company"), a biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases, presented its distinctive excellence at the 22nd edition of the annual congress of the American Society of Gene and Cell Therapy (ASGCT) the American scientific society of Gene and Cellular Therapies, ended today in Washington DC, (US).

The ASGCT congress, considered the most important in the field, involves doctors, scientists, researchers and technicians from all over the world with the aim of advancing knowledge and promoting innovation in the clinical application of gene and cell therapies to the benefit of patients.

MolMed joined the congress together with the major players in the field at a global level, presenting in two different sessions the continuous improvement and scale up processes used in the production of lentiviral vectors. MolMed is ranked among the leaders in the development and manufacturing of cell & gene therapies, counting many years of experience in the manufacturing of genetically modified cells, which as of today have already been used in the treatment of over 250 patients and in over 20 clinical studies, and a production capacity of vectors that reaches up to 200 litres per batch.

Thanks to the growth of the cell & gene field, MolMed continues its path of excellence to identify and develop the most efficient processes for large-scale production of lentiviral vectors according to Good Manufacturing Practices (GMP) to meet the growing market demand, including clinical trials on advanced therapies, in strong expansion.

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis®, that received orphan drug designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the Company is developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase; the product is potentially effective also in several epithelial solid tumors. With regards to allogeneic CARs, MolMed is developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization

FROM GENES TO THERAPY

1

PRESS RELEASE

for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the field of innovative oncological therapies MolMed pipeline also includes NGR-hTFN, a therapeutic agent for the treatment of solid tumors. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

For further information:
Ilaria Candotti	Tommasina Cazzato
Investor Relations & Communication Manager	Press Office
MolMed S.p.A.	Community Group
+39 02 21277.205	[phone]
[e-mail]	[e-mail]

FROM GENES TO THERAPY

2